Study name | Number of patients | CHA2DS2-VASc | Follow-up (months) | Total stroke/TIA follow-up | Stroke %/year | % Reduction | Death patient/ year | Antithrombotic therapy |
---|---|---|---|---|---|---|---|---|
Spanish Unicentre (ACP)14 | 35 | 3.94±1.89 | 21.14±10.1 | 2.85% (1/35) | 0% versus 5.45% | 5.04% | 3–6 m DAPT 3 m indefinite ASA | |
Partial ACP European postmarket | 145 | 3.7±1.7 | 24 | 2.12% (1/47) | 1.24% versus 5.33% | 65% | NA | 3 m DAPT 3 m ASA |
USA-European ASAP (Watch)13 | 150 | 4.4±1.7 | 14.4±8.6 | 2.6% (4/150) | 1.7% vs 7.3% | 77% | 5% | 6 m DAPT |
Canadian (ACP)15 | 52 | 5 (4–6) | 20±5 | 5.7% (3/52) | 1.1% vs 8.6% | 87% | 5.8% | 1–3 or 1–6 m |
Iberian multicentre (current) | 167 | 4 (3–6) | 22±8.3 | 4.2% (7/167) | 2.4% vs 9.6% | 75% | 5.8% | 3–6 m DAPT 6 m indefinite ASA |
Average of figures or percentages | 549 | 4.2 | 20.38 | 3.54% (16/451) | 1.28% vs 7.25% | 76% | 5.41% |
ACP, Amplatzer Cardiac Plug; ASA, aspirin; DAPT, double antiplatelet therapy; LAA, left atrial appendage; OAC, oral anticoagulant; TIA, transient ischaemic attack.